Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earns Hold Rating from Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research report issued to clients and investors on Monday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, Maxim Group upgraded shares of Brainstorm Cell Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 target price for the company in a report on Thursday, July 11th.

Brainstorm Cell Therapeutics Price Performance

BCLI stock opened at $0.24 on Monday. The stock has a market capitalization of $16.89 million, a price-to-earnings ratio of -0.75 and a beta of 0.35. The stock’s fifty day simple moving average is $0.31 and its 200-day simple moving average is $0.42. Brainstorm Cell Therapeutics has a 52-week low of $0.13 and a 52-week high of $0.79.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last issued its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.04). During the same period last year, the business earned ($0.27) earnings per share. As a group, analysts anticipate that Brainstorm Cell Therapeutics will post -0.19 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC acquired a new stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned approximately 0.12% of Brainstorm Cell Therapeutics at the end of the most recent reporting period. 14.33% of the stock is owned by hedge funds and other institutional investors.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.